Additionally, and as happens in any other predictive methodology, another major issue to address is the limited access to data , considering that several results that are regarded as of "no interest" for a particular study (at some point in time) are rarely published. This fact creates a crescent gap in the available information related to compounds associated with poor activity or side effects like DILI events.